H.C. Wainwright lowered the firm’s price target on Dynavax to $27 from $28 and keeps a Buy rating on the shares following the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DVAX:
- Dynavax reports Q4 EPS 45c, consensus 0c
- Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
- Dynavax reports results from Phase 1 trial of shingles vaccine Z-1018
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
- Dynavax reports Q4 preliminary HEPLISAV-B net product revenue $35M